TREX1 gene changes in adults with lupus who have skin symptoms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational genetic association study enrolling adults with SLE and at least one cutaneous manifestation at South Valley University hospitals in Qena, Egypt. Investigators will collect detailed clinical data, autoantibody profiles, and disease activity measures, and perform TREX1 genotyping to identify polymorphisms. The analysis will compare TREX1 variants with cutaneous phenotypes and measures of lupus activity to look for correlations. The goal is to fill gaps in data from Egyptian patients and to better characterize genetic contributions to cutaneous lupus.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult aged 18-60 years
* Diagnosed as SLE per 2019 EULAR/ACR classification criteria.
* Presence of at least one cutaneous manifestation (acute, subacute, or chronic).
* Willing to provide written informed consent for participation and genetic testing

Exclusion Criteria:

* Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis).
* Systemic infection, malignancy, or pregnancy.
* Use of biologic therapy or immunosuppressive pulses within one month.

Where it's running

• Qina University hospital, South Valley University Hospital
  Qina, South Valley, Egypt Recruiting

Study contacts

• Study coordinator: Amira Rabea AbuElfadl, MSc
• Email: Amirarabea575@gmail.com
• Phone: +201146299296

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Home urine testing for people with lupus

  Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.

  Recruiting NYU Langone Health · New York, New York · NCT07823478

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.